<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029415</url>
  </required_header>
  <id_info>
    <org_study_id>2018SDU-QILU-G114</org_study_id>
    <nct_id>NCT04029415</nct_id>
  </id_info>
  <brief_title>The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province</brief_title>
  <official_title>The Study of the Antimicrobial Resistance of Helicobacter Pylori in Shandong Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The antimicrobial resistance of helicobacter pylori in Shandong province was analyzed by
      helicobacter pylori antibiotic sensitivity test.And the map of antimicrobial resistance of
      helicobacter pylori was constructed to provide clinical guidance for selecting effective
      eradication program and improve the eradication rate.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients with positive H. pylori infection that was not eradicated by previous therapies
      will accept the gastroscopy. The mucosa of the lesser curvature of gastric antrum and the
      greater curvature of the stomach will progress helicobacter pylori antibiotic sensitivity
      test to detect the antimicrobial resistance of helicobacter pylori.The antimicrobial
      resistance of helicobacter pylori in Shandong province will be described by frequency and
      percentage.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Antimicrobial resistance rate</measure>
    <time_frame>3years</time_frame>
    <description>The antimicrobial resistance rate will be described by the frequency and percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The influence factors of the antimicrobial resistance rate</measure>
    <time_frame>3years</time_frame>
    <description>The chi-square test will be used to compare the influence factors of the antimicrobial resistance rate.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Helicobacter Pylori</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The gastric mucosa of the lesser curvature of gastric antrum and the greater curvature of the
      stomach
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The patients in Shandong province, aged between 18 and 70 years old, with positive H.
        pylori infection that was not eradicated by previous therapies are included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients, aged between 18 and 70 years old, with positive H. pylori infection that was
             not eradicated by previous therapies are included. The H. pylori infection is
             confirmed by the positive rapid urease test or 13C-breath test.

        Exclusion Criteria:

          -  Patients with significant underlying disease including liver, cardiac, pulmonary, and
             renal diseases, neoplasia, coagulopathy and genetic diseases, history of gastric
             surgery, pregnancy, breast-feeding, active gastrointestinal bleeding, the use of PPI,
             NSAID or antibiotics during the 4 weeks prior to enrolment, and previous history of
             allergic reactions to any of the medications used in this protocol. Patients
             previously treated with H. pylori eradication regimens or those unwilling to
             participate in the study were also excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tian Ma, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Qilu Hospital of Shandong University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuli Zuo, MD,PhD</last_name>
    <phone>15588818685</phone>
    <phone_ext>053188369277</phone_ext>
    <email>zuoxiuli@sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tian Ma, MD</last_name>
    <phone>18769781098</phone>
    <phone_ext>053188369277</phone_ext>
    <email>matian1002@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Qilu Hospital of Shandong University</name>
      <address>
        <city>Jinan</city>
        <state>Shandong</state>
        <zip>257000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiuli Zuo, MD,PhD</last_name>
      <phone>15588818685</phone>
      <phone_ext>053188369277</phone_ext>
      <email>zuoxiuli@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Tian Ma, MD</last_name>
      <phone>18769781098</phone>
      <phone_ext>053188369277</phone_ext>
      <email>matian1002@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Junnan Hu, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chen Qiao, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 21, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 21, 2019</last_update_submitted>
  <last_update_submitted_qc>July 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Xiuli Zuo</investigator_full_name>
    <investigator_title>director of Qilu Hospital gastroenterology department</investigator_title>
  </responsible_party>
  <keyword>antimicrobial resistance</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

